Abstract:Objective: The aim of this study was to evaluate the efficacy of a new ultrasound contrast agent, SonoVue, in diagnosis and differential diagnosis of liver lesions.Methods: Thirty-one patients with difficult differential diagnosis or highly suspected for liver lesions on CT, MRI, or conventional US were studied. A dose of 2.4 ml of SonoVue (Bracco, Italy) was infused intravenously within 30 sec. The enhancement level was monitored with a nonlinear scanning mode using an Acuson Sequoia-512 scanner with 6C-2, 4C-1 probes. The comparison examinations were performed with physical examination in all cases and with library examination in 16 patients before and after SonoVue injection. The histopathalogical diagnoses were obtained in 20 patients after SonoVue enhanced US examination. The other diagnoses were confirmed on CT, MRI, and DSA. Twenty patients had malignant liver lesions (16 hepatocellular carcinomas, 4 metastases), while 11 had benign lesions (4 hemangiomas, 2 focal nodular hyperplasias, 5 others).Results: 1) After SonoVue injection, the number of lesions without flow signal intralesions dropped from 15 to 2 with nonlinear scanning modes. 2) The positive diagnoses compared to the histopathalogical diagnoses increased after SonoVue in nonlinear scanning modes (p<0.05). 3) There was no difference in physical examination and library examinations before and after SonoVue injection.Conclusions: SonoVue is useful in visualizing tumor vessel and characterizing liver tumors. It is a safe, efficient ultrasound contrast agent and convenient for use. Objective: The aim of this study was to evaluate the efficacy of a new ultrasound contrast agent, SonoVue, in diagnosis and differential diagnosis of liver lesions. Methods: Thirty-one patients with difficult differential diagnosis or highly suspected for liver lesions on CT, MRI, or conventional US were studied. A dose of 2.4 ml of SonoVue (Bracco, Italy) was infused intravenously within 30 sec. The enhancement level was monitored with a nonlinear scanning mode using an Acuson Sequoia-512 scanner with 6C-2, 4C-1 probes. The comparison examinations were performed with physical examination in all cases and with library examination in 16 patients before and after SonoVue injection. The histopathalogical diagnoses were obtained in 20 patients after SonoVue enhanced US examination. The other diagnoses were confirmed on CT, MRI, and DSA. Twenty patients had malignant liver lesions (16 hepatocellular carcinomas, 4 metastases), while 11 had benign lesions (4 hemangiomas, 2 focal nodular hyperplasias, 5 others). Results: 1) After SonoVue injection, the number of lesions without flow signal intralesions dropped from 15 to 2 with nonlinear scanning modes. 2) The positive diagnoses compared to the histopathalogical diagnoses increased after SonoVue in nonlinear scanning modes (p<0.05). 3) There was no difference in physical examination and library examinations before and after SonoVue injection. Conclusions: SonoVue is useful in visualizing tumor vessel and characterizing liver tumors. It is a safe, efficient ultrasound contrast agent and convenient for use.

Intra-individual comparison of Sonazoid contrast-enhanced ultrasound and SonoVue contrast-enhanced ultrasound in diagnosing hepatocellular carcinoma

Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid

The Clinical Use of Contrast - Enhanced Gray - Scale Ultrasonography in the Diagnosis of Focal Liver Lesions

[Application Value of Contrast-Enhanced Ultrasonography for Assessing the High-Risk Population of Hepatic Malignant Tumor].

Improved differential diagnosis of focal liver disease using SonoVue with nonlinear scanning mode

Perfluorobutane (Sonazoid) Contrast-enhanced ultrasound to diagnose hepatocellular carcinoma: A systematic review and meta-analysis

Ultrasonography of Hepatocellular Carcinoma: from Diagnosis to Prognosis

Diagnostic value and comparison of hepatic cell carcinoma by contrast-enhanced ultrasound with the types of agents: SonoVue and Opeison

Assessment of Arterial-Phase Hyperenhancement and Late-Phase Washout of Hepatocellular Carcinoma—a Meta-Analysis of Contrast-Enhanced Ultrasound (CEUS) with SonoVue® and Sonazoid®

Compared with SonoVue ® LR-5, Sonazoid ® modified LR-5 has better diagnostic sensitivity for hepatocellular carcinoma: a systematic review and meta-analysis

Comparison Between SonoVue and Sonazoid Contrast‐Enhanced Ultrasound in Characterization of Focal Nodular Hyperplasia Smaller Than 3 Cm

A Review of Contrast-enhanced Ultrasound using SonoVue® and Sonazoid TM in Non-hepatic Organs

Contrast-Enhanced Ultrasound With SonoVue and Sonazoid for the Diagnosis of Colorectal Liver Metastasis After Chemotherapy.

A Comparative Study of SonoVue and Sonazoid for Contrast-Enhanced Ultrasound CT/MRI Fusion Guidance During Radiofrequency Ablation of Poorly Visualized Hepatic Malignancies: A Prospective Intra-Individual Analysis

Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis

Prospective Assessment of Diagnostic Efficacy and Safety of SonazoidTM and SonoVue® Ultrasound Contrast Agents in Patients with Focal Liver Lesions

Diagnostic Test Accuracy of Contrast‐Enhanced Ultrasound With Sonazoid for Assessment of Focal Liver Lesions: A Systematic Review and Meta‐Analysis

Comparison of Sonazoid-Contrast‑Enhanced Ultrasound and Gd‑EOB‑DTPA‑Enhanced MRI for Predicting Microvascular Invasion in Hepatocellular Carcinoma

Comparison of SonoVue-enhanced harmonic gray-scale and fundamental color Doppler US in detecting vascularity in liver lesions

Comparison of SonoVue and Sonazoid in Localization of Sentinel Lymph Nodes in Early Breast Cancer Patients

Development and Comparison of Prediction Models Based on Sonovue- and Sonazoid-Enhanced Ultrasound for Pathologic Grade and Microvascular Invasion in Hepatocellular Carcinoma